The company intends to commence the trial in the second half of this year.
The trial will analyze SNIPR001’s safety and tolerability and its effect on decreasing the colonization of E. Coli in the gut.
Cynata Therapeutics has started clinical trials with an initial cohort of patients in Adelaide of its patented product, aimed at treating diabetic foot ulcers.
Global pharmaceutical companies have been running clinical trials in Latin America for over 20 years.
The Trial-Ready Cohort Study will offer data for the planned Phase I/IIa trial of ANPD001.
The trial will assess the monthly and alternate-month dosing regimen of ANX007 in 270 patients.
The trial will analyze the safety, tolerability and efficacy of YH003, YH001 and pembrolizumab in solid tumor patients.
The trial will assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020.
The relative change from baseline in body weight at 48 weeks following pemvidutide treatment is the trial’s primary endpoint.
In the trial, both the tested doses of rNAPc2 demonstrated to be well-tolerated.